Search | Clinical Trials Finder

Conditions: Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
Interventions: High-dose Methotrexate; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 7 Years to 22 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 5 more

Conditions: Bladder Cancer
Interventions: cisplatin, docetaxel, gemcitabine hydrochloride, methotrexate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 4
States / cities: Chicago, Illinois • Peoria, Illinois • Fort Wayne, Indiana

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions: asparaginase, cyclophosphamide, cytarabine, dexamethasone, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, prednisolone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 1 Year to 18 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 2 more

Conditions: Gout
Interventions: Pegloticase, Methotrexate; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 74
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 63 more

Conditions: Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions: Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2050
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Interventions: First Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT, Cyclophosphamide, Methotrexate, Tacrolimus, Total Body Irradiation, Busulfan, Fludarabine, Second Allogeneic Bone Marrow Transplantation; Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland • Oklahoma City, Oklahoma

Conditions: Uncontrolled Gout
Interventions: Pegloticase, Methotrexate (MTX); Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Glendale, Arizona + 12 more

Conditions: Hematologic Malignancy, Myeloid Malignancy
Interventions: Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan, Thiotepa; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 12 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Uncontrolled Gout, Chronic Gout
Interventions: Pegloticase, Methotrexate (MTX); Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Anchorage, Alaska • Glendale, Arizona • San Leandro, California + 9 more

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Anemia, Refractory, With Excess of Blasts
Interventions: IGF/MTX; Drug
Lead sponsor: IGF Oncology, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Rochester, Minnesota • Saint Paul, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin; Drug · Biological
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 34
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Lymphoblastic Leukemia
Interventions: Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 20
States / cities: Duarte, California • Long Beach, California • Los Angeles, California + 16 more

Conditions: Uncontrolled Gout
Interventions: Pegloticase, Methotrexate; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 70
States / cities: Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 53 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions: Isatuximab, Dexamethasone or equivalent, Fludarabine, Cytarabine, Liposomal daunorubicin, Daunorubicin (nonliposomal), Idarubicin, Filgrastim or equivalent, Mitoxantrone, Doxorubicin, Vincristine, Pegaspargase (PEG) Asparaginase, Cyclophosphamide, Etoposide, Methotrexate, L - Asparginase, Hydroxyurea, L - Asparaginase (Erwinase); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 28 Days to 17 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Nashville, Tennessee • Dallas, Texas

Conditions: Leukemia, Acute Lymphocytic Leukemia
Interventions: Everolimus (RAD001), Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Mesna, Methotrexate, Ara-C (Cytarabine), Methylprednisone, G-CSF; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoblastic Leukemia, Acute, Childhood
Interventions: Clofarabine incorporated into a 5-drug regimen; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 1 Year to 30 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, dose level 1, dose level 2, dose level 3, dose level 4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Daytona Beach, Florida • Ormond Beach, Florida • Duncansville, Pennsylvania

Conditions: Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions: ATG dosing platform when combined with standard tacrolimus and mini methotrexate; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions: Afatinib, Methotrexate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 8
States / cities: Harvey, Illinois • Peoria, Illinois • Boston, Massachusetts + 4 more

Conditions: Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: Sirolimus, Methotrexate, Tacrolimus, Cyclosporine, MMF; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 72 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 1 more

Conditions: Leukemia
Interventions: cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, Total Body Irradiation, Busulfan, Mesna, Radiation; Drug · Procedure · Radiation
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 21 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 17
States / cities: Birmingham, Alabama • San Diego, California • Jacksonville, Florida + 11 more

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], methotrexate, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 21
States / cities: Santa Monica, California • Upland, California • Whittier, California + 18 more

Conditions: Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
Interventions: alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 9
States / cities: Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more

Search by objective public record fields.

The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

CHronic Nonbacterial Osteomyelitis International Registry

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)

Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors